Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial.

Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF, Waseda K, Hlatky MA; BARI-2D Study Group.

J Am Coll Cardiol. 2017 Jan 31;69(4):395-403. doi: 10.1016/j.jacc.2016.10.067.

2.

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes.

Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group.

N Engl J Med. 2015 Aug 13;373(7):610-20. doi: 10.1056/NEJMoa1415921.

3.

The Women on the Move Through Activity and Nutrition (WOMAN) study: final 48-month results.

Kuller LH, Pettee Gabriel KK, Kinzel LS, Underwood DA, Conroy MB, Chang Y, Mackey RH, Edmundowicz D, Tyrrell KS, Buhari AM, Kriska AM.

Obesity (Silver Spring). 2012 Mar;20(3):636-43. doi: 10.1038/oby.2011.80. Epub 2011 Apr 14.

4.

The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Singh PP, Abbott JD, Lombardero MS, Sutton-Tyrrell K, Woodhead G, Venkitachalam L, Tsapatsaris NP, Piemonte TC, Lago RM, Rutter MK, Nesto RW; Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group.

Diabetes Care. 2011 Feb;34(2):464-7. doi: 10.2337/dc10-1734.

5.

A randomized trial of therapies for type 2 diabetes and coronary artery disease.

BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE.

N Engl J Med. 2009 Jun 11;360(24):2503-15. doi: 10.1056/NEJMoa0805796. Epub 2009 Jun 7.

6.

Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.

Pop-Busui R, Lu J, Lopes N, Jones TL; BARI 2D Investigators.

J Peripher Nerv Syst. 2009 Mar;14(1):1-13. doi: 10.1111/j.1529-8027.2009.00200.x.

7.

Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group.

Am Heart J. 2008 Sep;156(3):528-536, 536.e1-5. doi: 10.1016/j.ahj.2008.05.015. Epub 2008 Jul 31.

8.

Subclinical atherosclerosis and estimated glucose disposal rate as predictors of mortality in type 1 diabetes.

Olson JC, Erbey JR, Williams KV, Becker DJ, Edmundowicz D, Kelsey SF, Tyrrell KS, Orchard TJ.

Ann Epidemiol. 2002 Jul;12(5):331-7.

PMID:
12062921
9.

Patients with Glanzmann thrombasthenia lacking platelet glycoprotein alpha(IIb)beta(3) (GPIIb/IIIa) and alpha(v)beta(3) receptors are not protected from atherosclerosis.

Shpilberg O, Rabi I, Schiller K, Walden R, Harats D, Tyrrell KS, Coller B, Seligsohn U.

Circulation. 2002 Mar 5;105(9):1044-8.

10.

Mortality over four years in SHEP participants with a low ankle-arm index.

Newman AB, Tyrrell KS, Kuller LH.

J Am Geriatr Soc. 1997 Dec;45(12):1472-8.

PMID:
9400557
11.

Prevalence and determinants of carotid atherosclerosis in healthy postmenopausal women.

Lassila HC, Tyrrell KS, Matthews KA, Wolfson SK, Kuller LH.

Stroke. 1997 Mar;28(3):513-7.

Supplemental Content

Loading ...
Support Center